KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Shares Outstanding for 8 consecutive years, with $153.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.06% to $153.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.8 million through Dec 2025, up 4.06% year-over-year, with the annual reading at $153.8 million for FY2025, 4.06% up from the prior year.
  • Shares Outstanding hit $153.8 million in Q4 2025 for Adaptive Biotechnologies, up from $152.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $153.8 million in Q4 2025 to a low of $139.9 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $145.7 million across 5 years, with a median of $144.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding: increased 10.47% in 2021 and later rose 1.21% in 2022.
  • Year by year, Shares Outstanding stood at $141.4 million in 2021, then increased by 1.21% to $143.1 million in 2022, then rose by 1.38% to $145.1 million in 2023, then grew by 1.86% to $147.8 million in 2024, then rose by 4.06% to $153.8 million in 2025.
  • Business Quant data shows Shares Outstanding for ADPT at $153.8 million in Q4 2025, $152.6 million in Q3 2025, and $152.2 million in Q2 2025.